Refining Gross-to-Net Expectations for Strategic Planning

This research article explores the complexities of gross-to-net (GTN) dynamics in the biopharma industry, emphasizing the importance of understanding GTN components for effective commercial strategy and market access. It highlights trends, implications, and the evolving nature of GTN, particularly in the context of recent regulatory changes and market conditions. Key insights are provided on how GTN influences pricing strategies and the overall success of pharmaceutical products.